{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:31:11Z","timestamp":1787668271170,"version":"build-2736575974"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T00:00:00Z","timestamp":1663027200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T00:00:00Z","timestamp":1663027200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Granulocyte colony-stimulating factor (G-CSF)-producing lung cancer induces severe inflammation and a high white blood cell (WBC) count and is associated with poor prognosis. A recent case of G-CSF-producing lung adenocarcinoma showed high expression of programmed cell death ligand 1 (PD-L1) and was treated with pembrolizumab as first-line therapy, which was extremely effective. We hypothesized that G-CSF-producing lung cancers are associated with high PD-L1 expression.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This retrospective study included patients diagnosed with lung cancer at Yokohama Municipal Citizen\u2019s Hospital (Kanagawa, Japan) between 2009 and 2019. The PD-L1 status of 13 patients with high plasma G-CSF levels (\u226540 pg\/mL) was assessed by conducting immunohistochemical analysis of tissue samples.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of the total patients, 11 were men and 2 were women, with a median age of 74 years (70\u201385 years). Four, five, and three patients had adenocarcinoma, squamous cell carcinoma, and others, respectively. The median G-CSF level and WBC count were 85.5 pg\/mL (range, 40.8\u2013484 pg\/mL) and 15,550\/\u03bcL (range, 6,190\u201356,800\/\u03bcL), respectively. The PD-L1 tumor proportion scores (TPSs) were \u226550%, 1%\u201349%, and &lt;1% in 9, 1, and 3 patients, respectively. The median overall survival time was 7.3 months. Pembrolizumab was administered in six patients as first-line treatment, with two patients showing partial response, one patient with stable disease, and three patients with progressive disease. All six patients had a PD-L1 TPS of \u226550%.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>G-CSF-producing lung cancers may be associated with increased PD-L1 expression. Although immune checkpoint inhibitors are an important treatment option for G-CSF-producing tumors, their effects are limited.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-022-10065-w","type":"journal-article","created":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T02:05:07Z","timestamp":1663034707000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Programmed cell death ligand 1 measurement study in granulocyte colony-stimulating factor-producing lung cancer: an observational study"],"prefix":"10.1186","volume":"22","author":[{"given":"Kazuhito","family":"Miyazaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Shiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiki","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Higashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaharu","family":"Aga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Hamakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Misumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Agemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiko","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuneo","family":"Shimokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,13]]},"reference":[{"key":"10065_CR1","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1126\/science.2990035","volume":"229","author":"D Metcalf","year":"1985","unstructured":"Metcalf D. The granulocyte-macrophage colony-stimulating factors. Science. 1985;229:16\u201322. https:\/\/doi.org\/10.1126\/science.2990035.","journal-title":"Science."},{"key":"10065_CR2","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/319415a0","volume":"319","author":"S Nagata","year":"1986","unstructured":"Nagata S, Tsuchiya M, Asano S, et al. Molecular cloning and expression of cDNA for human granulocyte colony-stimulating factor. Nature. 1986;319:415\u20138. https:\/\/doi.org\/10.1038\/319415a0.","journal-title":"Nature."},{"key":"10065_CR3","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1182\/blood.V49.5.845.845","volume":"49","author":"S Asano","year":"1977","unstructured":"Asano S, Urabe A, Okabe T, et al. Demonstration of granulopoietic factor(s) in the plasma of nude mice transplanted with a human lung cancer and in the tumor tissue. Blood. 1977;49:845\u201352.","journal-title":"Blood."},{"key":"10065_CR4","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1159\/000508439","volume":"14","author":"Y Morita","year":"2020","unstructured":"Morita Y, Sakaguchi T, Ida S, et al. Aggressive Recurrent Pancreatic Cancer Producing Granulocyte Colony-Stimulating Factor. Case Rep Gastroenterol. 2020;14:329\u201337. https:\/\/doi.org\/10.1159\/000508439.","journal-title":"Case Rep Gastroenterol."},{"key":"10065_CR5","doi-asserted-by":"publisher","first-page":"687","DOI":"10.2169\/internalmedicine.48.1900","volume":"48","author":"S Joshita","year":"2009","unstructured":"Joshita S, Nakazawa K, Sugiyama Y, et al. Granulocyte-Colony Stimulating Factor-Producing Pancreatic Adenosquamous Carcinoma Showing Aggressive Clinical Course. Intern Med. 2009;48:687\u201391. https:\/\/doi.org\/10.2169\/internalmedicine.48.1900.","journal-title":"Intern Med."},{"key":"10065_CR6","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodr\u00edguez-Abreu D, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016;375:1823\u201333. https:\/\/doi.org\/10.1056\/NEJMoa1606774.","journal-title":"N Engl J Med."},{"key":"10065_CR7","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","volume":"372","author":"EB Garon","year":"2015","unstructured":"Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372:2018\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1501824.","journal-title":"N Engl J Med."},{"key":"10065_CR8","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s12149-008-0146-z","volume":"22","author":"M Morooka","year":"2008","unstructured":"Morooka M, Kubota K, Murata Y, et al. (18)F-FDG-PET\/CT findings of granulocyte colony stimulating factor (G-CSF)-producing lung tumors. Ann Nucl Med. 2008;22:635\u20139. https:\/\/doi.org\/10.1007\/s12149-008-0146-z.","journal-title":"Ann Nucl Med."},{"key":"10065_CR9","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.3892\/ol.2017.7422","volume":"15","author":"T Kuroshima","year":"2018","unstructured":"Kuroshima T, Wada M, Sato T, et al. G-CSF producing oral carcinoma with diffuse uptake of FDG in the bone marrow: A case report. Oncol Lett. 2018;15:1241\u20135. https:\/\/doi.org\/10.3892\/ol.2017.7422.","journal-title":"Oncol Lett."},{"key":"10065_CR10","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3892\/mco.2017.1271","volume":"7","author":"T Makino","year":"2017","unstructured":"Makino T, Hata Y, Otsuka H, et al. Diffuse fluorodeoxyglucose-positron uptake in the bone marrow of a patient with granulocyte colony-stimulating factor-producing pleomorphic carcinoma of the lung: A case report. Mol Clin Oncol. 2017;7:103\u20136. https:\/\/doi.org\/10.3892\/mco.2017.1271.","journal-title":"Mol Clin Oncol."},{"key":"10065_CR11","doi-asserted-by":"publisher","first-page":"3305","DOI":"10.2169\/internalmedicine.2819-19","volume":"58","author":"Y Yoshida","year":"2019","unstructured":"Yoshida Y, Sibusa T, Ishii Y, et al. Granulocyte Colony-stimulating Factorf and Interleukin-6-producing Large-cell Carcinoma of the Lung with Sarcomatoid Changes Suggestive of Epithelial-mesenchymal Transition: An Autopsy Case Report. Intern Med. 2019;58:3305\u201311. https:\/\/doi.org\/10.2169\/internalmedicine.2819-19.","journal-title":"Intern Med."},{"key":"10065_CR12","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","volume":"11","author":"T Mitsudomi","year":"2010","unstructured":"Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor(WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010;11:121\u20138.","journal-title":"Lancet Oncol."},{"key":"10065_CR13","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","volume":"371","author":"BJ Solomon","year":"2014","unstructured":"Solomon BJ, Mok T, Kim DW, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371:2167\u201377.","journal-title":"N Engl J Med."},{"key":"10065_CR14","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(17)30565-2","volume":"390","author":"T Hida","year":"2017","unstructured":"Hida T, Nokihara H, Kondo M, et al. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer(J-ALEX): an open-label, randomised phase 3 trial. Lancet. 2017;390:29\u201339.","journal-title":"Lancet."},{"key":"10065_CR15","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","volume":"393","author":"TSK Mok","year":"2019","unstructured":"Mok TSK, Wu YL, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393:1819\u201330.","journal-title":"Lancet."},{"key":"10065_CR16","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","volume":"373","author":"J Brahmer","year":"2015","unstructured":"Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in Advanced squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015;373:123\u201335.","journal-title":"N Engl J Med."},{"key":"10065_CR17","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in Advanced nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015;373:1627\u201339.","journal-title":"N Engl J Med."},{"key":"10065_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000678","volume":"8","author":"A Keegan","year":"2020","unstructured":"Keegan A, Ricciuti B, Garden P, et al. Plasma IL-6 changes correlate to PD-1 inhibitor responses in NSCLC. J Immunother Cancer. 2020;8:e000678. https:\/\/doi.org\/10.1136\/jitc-2020-000678.","journal-title":"J Immunother Cancer."}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-10065-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-022-10065-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-10065-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T02:05:43Z","timestamp":1663034743000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-022-10065-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,13]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["10065"],"URL":"https:\/\/doi.org\/10.1186\/s12885-022-10065-w","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,13]]},"assertion":[{"value":"30 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was conducted in accordance with the ethical standards of the Institutional and\/or National Research Committee and the Declaration of Helsinki (1964) and its later amendments or comparable ethical standards, and approved by the Ethics Committee of the IRB of Yokohama Municipal Citizen\u2019s Hospital, Kanagawa, Japan (approval number: 19-03-05). Informed consent was obtained through an opt-out method on the hospital\u2019s website because this was a retrospective study. None of the patients were excluded from the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no financial relationships relevant to the work contained in this article and no other conflicts of interest to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"977"}}